Steffen Borrmann

Summary

Affiliation: Kenya Medical Research Institute
Country: Kenya

Publications

  1. ncbi Fosmidomycin for the treatment of malaria
    Jochen Wiesner
    Jomaa Pharmaka GmbH, Frankfurter Strasse 50, 35392 Giessen, Germany
    Parasitol Res 90:S71-6. 2003
  2. ncbi Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children
    Steffen Borrmann
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon
    Clin Infect Dis 37:1441-7. 2003
  3. ncbi Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria
    Steffen Borrmann
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon, Germany
    J Infect Dis 190:1534-40. 2004
  4. pmc Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children
    Steffen Borrmann
    Institute of Hygiene, University of Heidelberg, School of Medicine, Heidelberg, Germany
    Antimicrob Agents Chemother 52:1799-805. 2008
  5. pmc Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria
    Steffen Borrmann
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon
    Antimicrob Agents Chemother 49:3749-54. 2005
  6. pmc Temporal association of acute hepatitis A and Plasmodium falciparum malaria in children
    Peter Klein Klouwenberg
    University Medical Center Utrecht, Utrecht, The Netherlands
    PLoS ONE 6:e21013. 2011
  7. pmc Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast
    Steffen Borrmann
    Kenya Medical Research Institute Wellcome Trust Research Programme, Kilifi, Kenya
    PLoS ONE 6:e26005. 2011
  8. doi Protective immunity against malaria by 'natural immunization': a question of dose, parasite diversity, or both?
    Steffen Borrmann
    Clinical Parasitology Unit, Heidelberg University School of Medicine, 69120 Heidelberg, Germany
    Curr Opin Immunol 23:500-8. 2011
  9. doi Targeting Plasmodium liver stages: better late than never
    Steffen Borrmann
    Department of Infectious Diseases, Heidelberg University School of Medicine, 69120 Heidelberg, Germany
    Trends Mol Med 17:527-36. 2011
  10. pmc In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1
    Leah Mwai
    Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, Kilifi, Kenya
    Antimicrob Agents Chemother 53:5069-73. 2009

Collaborators

Detail Information

Publications32

  1. ncbi Fosmidomycin for the treatment of malaria
    Jochen Wiesner
    Jomaa Pharmaka GmbH, Frankfurter Strasse 50, 35392 Giessen, Germany
    Parasitol Res 90:S71-6. 2003
    ..In drug combination studies, synergy of fosmidomycin with clindamycin was observed. Clinical studies with a fosmidomycin-clindamycin combination are currently ongoing...
  2. ncbi Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children
    Steffen Borrmann
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon
    Clin Infect Dis 37:1441-7. 2003
    ..Atovaquone/proguanil was found to be highly effective and safe for the treatment of Plasmodium falciparum malaria in infants and young children weighing 5-10 kg in Africa...
  3. ncbi Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria
    Steffen Borrmann
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon, Germany
    J Infect Dis 190:1534-40. 2004
    ..Fosmidomycin-clindamycin is safe and well tolerated, and short-course regimens achieved high efficacy in children with P. falciparum malaria. Fosmidomycin-clindamycin is a promising novel treatment option for malaria...
  4. pmc Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children
    Steffen Borrmann
    Institute of Hygiene, University of Heidelberg, School of Medicine, Heidelberg, Germany
    Antimicrob Agents Chemother 52:1799-805. 2008
    ..The thresholds may vary by transmission intensity and drug regimen. A better understanding of the limitations of antimalarial regimens in high-risk subgroups of patients has important implications for setting policy recommendations...
  5. pmc Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria
    Steffen Borrmann
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon
    Antimicrob Agents Chemother 49:3749-54. 2005
    ..Artesunate-fosmidomycin demonstrates the feasibility and potential value of short-course artemisinin-based combination chemotherapy with rapidly eliminated combination partners...
  6. pmc Temporal association of acute hepatitis A and Plasmodium falciparum malaria in children
    Peter Klein Klouwenberg
    University Medical Center Utrecht, Utrecht, The Netherlands
    PLoS ONE 6:e21013. 2011
    ..In sub-Saharan Africa, Plasmodium falciparum and hepatitis A (HAV) infections are common, especially in children. Co-infections with these two pathogens may therefore occur, but it is unknown if temporal clustering exists...
  7. pmc Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast
    Steffen Borrmann
    Kenya Medical Research Institute Wellcome Trust Research Programme, Kilifi, Kenya
    PLoS ONE 6:e26005. 2011
    ..The emergence of artemisinin-resistant P. falciparum malaria in South-East Asia highlights the need for continued global surveillance of the efficacy of artemisinin-based combination therapies...
  8. doi Protective immunity against malaria by 'natural immunization': a question of dose, parasite diversity, or both?
    Steffen Borrmann
    Clinical Parasitology Unit, Heidelberg University School of Medicine, 69120 Heidelberg, Germany
    Curr Opin Immunol 23:500-8. 2011
    ..This previously unrecognized immunological benefit might also open new opportunities for population-wide presumptive drug administration as an adjunct malaria control tool...
  9. doi Targeting Plasmodium liver stages: better late than never
    Steffen Borrmann
    Department of Infectious Diseases, Heidelberg University School of Medicine, 69120 Heidelberg, Germany
    Trends Mol Med 17:527-36. 2011
    ..Here, we review the basis, evidence and targets for whole-cell-based vaccination strategies against the liver stage bottleneck in Plasmodium infections and discuss preclinical and clinical research opportunities...
  10. pmc In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1
    Leah Mwai
    Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, Kilifi, Kenya
    Antimicrob Agents Chemother 53:5069-73. 2009
    ..Therefore, the use of LM-artemether is likely to lead to the selection of more CQ-susceptible parasites...
  11. doi The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria
    Steffen Borrmann
    Institute of Hygiene, University of Heidelberg School of Medicine, Germany
    Trop Med Int Health 15:434-41. 2010
    ..e. children, are lacking. Therefore, we evaluated the effect of food intake on oral lumefantrine bioavailability in African children with malaria...
  12. pmc Chloroquine resistance before and after its withdrawal in Kenya
    Leah Mwai
    Kenya Medical Research Institute Wellcome Trust Collaborative Research Programme, Kilifi, Kenya
    Malar J 8:106. 2009
    ..Changes to those that occurred in the dihydrofolate reductase gene (dhfr) that confers resistance to the replacement drug, pyrimethamine/sulphadoxine were also compared...
  13. doi In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-aminoquinolines in East Africa
    Philip Sasi
    Kenya Medical Research Institute, Center for Geographic Medicine Research Coast, Kilifi, Kenya
    J Infect Dis 199:1575-82. 2009
    ..These findings also suggest that the value of amodiaquine combinations as first- or second-line treatment in areas with similar patterns of 4-aminoquinoline resistance should be reassessed...
  14. doi Natural immunization against malaria: causal prophylaxis with antibiotics
    Johannes Friesen
    Department of Infectious Diseases, Heidelberg University School of Medicine, 69120 Heidelberg, Germany
    Sci Transl Med 2:40ra49. 2010
    ..If confirmed in residents of malaria-endemic areas, periodic prophylaxis with safe and affordable antibiotics may offer a powerful shortcut toward a needle-free surrogate malaria immunization strategy...
  15. pmc Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya
    Steffen Borrmann
    1 KEMRI Wellcome Trust Research Programme, Kilifi, Kenya 2 Institute of Microbiology, Magdeburg University School of Medicine, Germany
    Sci Rep 3:3318. 2013
    ..Our study provides a unique reference for the interpretation of results from resistant infections. ..
  16. ncbi Vaccine-like immunity against malaria by repeated causal-prophylactic treatment of liver-stage Plasmodium parasites
    Elyzana Dewi Putrianti
    1Department of Parasitology, Heidelberg University School of Medicine, Heidelberg, Germany
    J Infect Dis 199:899-903. 2009
    ..Pharmacological inhibition of liver-stage parasites in the rodent malaria model offers a potential fast track toward development of a vaccine that targets parasites in preerythrocytic stages...
  17. pmc Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya
    Ally Olotu
    Kenya Medical Research Institute Wellcome Trust Research Programme, Centre for Geographic Medicine Research, Kilifi, Kenya
    PLoS ONE 5:e15569. 2010
    ..Subjective and objective fevers are both used to define the endpoint, but have not been carefully compared, and the relative incidence of clinical malaria by active and passive case detection is unknown...
  18. pmc Induction of antimalaria immunity by pyrimethamine prophylaxis during exposure to sporozoites is curtailed by parasite resistance
    Johannes Friesen
    Parasitology Unit, Max Planck Institute for Infection Biology, 10117 Berlin
    Antimicrob Agents Chemother 55:2760-7. 2011
    ..Our data provide a rationale for the notion of sustained protective efficacy of IPT based on the capacity of arrested, drug-sensitive liver-stage and/or suppressed blood-stage parasites to mount lasting protection...
  19. pmc Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysis
    Johannes Pfeil
    Centre for Childhood and Adolescent Medicine and Department of Infectious Diseases, University Hospital, Heidelberg, Germany German Centre for Infection Research DZIF, Heidelberg, Germany
    PLoS ONE 9:e95681. 2014
    ....
  20. pmc Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria
    Steffen Borrmann
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon
    Antimicrob Agents Chemother 50:2713-8. 2006
    ..The inadequate efficacy in children of <3 years highlights the need for continued systematic studies of the current dosing regimen, which should include randomized trial designs...
  21. ncbi Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria
    Denise P Mawili-Mboumba
    Unité de Recherche Médicale, Hopital Albert Schweitzer, Lambarene, Gabon
    J Infect Dis 187:1137-41. 2003
    ..029). These results suggest that humoral immune responses play a supportive role in the efficacy of amodiaquine treatment...
  22. pmc Short-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon
    Steffen Borrmann
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon
    Antimicrob Agents Chemother 47:901-4. 2003
    ..We conclude that a 3-day course of artesunate fails to achieve sufficiently high cure rates for uncomplicated falciparum malaria in Gabonese children...
  23. ncbi Delayed parasite elimination in human infections treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro
    Dominik Burkhardt
    Department of Parasitology, Institute of Tropical Medicine, University of Tubingen, Germany
    Int J Parasitol 37:777-85. 2007
    ..The delayed, but potent, antimalarial effect of clindamycin appears to be of greatest potential benefit in new combinations of clindamycin with rapidly acting antimalarial combination partners...
  24. ncbi Fosmidomycin for malaria
    Michel A Missinou
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon
    Lancet 360:1941-2. 2002
    ..These data suggest that fosmidomycin is a safe and effective treatment for uncomplicated malaria if given for 4 days or more...
  25. ncbi Severe malaria in a splenectomised Gabonese woman
    Martin P Grobusch
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon
    Wien Klin Wochenschr 115:63-5. 2003
    ..Splenectomised individuals are at high risk to develop a more severe and prolonged disease, even if they had acquired semi-immunity prior to their loss of splenic tissue...
  26. ncbi Severe malarial anemia associated with increased soluble Fas ligand (sFasL) concentrations in Gabonese children
    Saadou Issifou
    Unite de Recherches Medicales, Hopital Albert Schweitzer, Lambarene, Gabon
    Eur Cytokine Netw 14:238-41. 2003
    ..These results suggest that, in malaria, a specific dysregulation of the cytokine balance may lead to complications such as severe anemia...
  27. ncbi Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children
    Steffen Borrmann
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon
    J Infect Dis 189:901-8. 2004
    ....
  28. ncbi Randomized controlled trial of a traditional preparation of Artemisia annua L. (Annual Wormwood) in the treatment of malaria
    Markus S Mueller
    German Institute for Medical Mission, P O Box 1307, 72003 Tübingen, Germany
    Trans R Soc Trop Med Hyg 98:318-21. 2004
    ..However, recrudescence rates were high in the Artemisia groups. Therefore, monotherapy with Artemisia annua L. cannot be recommended as alternative to modern antimalarials, but may deserve further investigation...
  29. pmc Assessment of volume depletion in children with malaria
    Timothy Planche
    Department of Cellular and Molecular Medicine, Infectious Diseases, St George s Hospital Medical School, London, United Kingdom
    PLoS Med 1:e18. 2004
    ..To assist management of severely ill children, and to test the hypothesis that volume changes in fluid compartments reflect disease severity, we measured body compartment volumes in Gabonese children with malaria...
  30. ncbi Clinical and parasitological characteristics of puerperal malaria
    Michael Ramharter
    Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon, Germany
    J Infect Dis 191:1005-9. 2005
    ..Recent findings indicate that this increased risk might persist beyond delivery, but the underlying mechanisms for this change in risk are poorly understood...
  31. ncbi Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial
    Michael Ramharter
    Albert Schweitzer Hospital, Lambarene, Gabon, Germany
    Clin Infect Dis 40:1777-84. 2005
    ..We tested the potential value of artemisinin-based combination therapy with a short elimination half-life for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa...
  32. ncbi Age-dependent enhancement of IFN-gamma responses to Plasmodium falciparum liver stage antigen-1 T cell epitopes
    Martina Bongartz
    Department of Parasitology, Institute of Tropical Medicine, University of Tubingen, Tubingen, Germany
    Parasitol Res 88:1083-9. 2002
    ..The results suggest a significant age-related increase in the proportion of individuals capable of producing IFN-gamma to the N-terminal T1 epitope, with a shift from a predominantly IL-10-led response in children...